These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1948452)

  • 1. [Interleukin 6 and disease].
    Kaisho T; Hirano T
    Ryumachi; 1991 Jun; 31(3):318-26. PubMed ID: 1948452
    [No Abstract]   [Full Text] [Related]  

  • 2. Membranoproliferative glomerulonephritis, p-antineutrophil cytoplasmic antibodies, and rheumatoid arthritis. Report of a case.
    Constantin A; Laroche M; Moulinier L; Bon E; Mazières B; Cantagrel A
    Rev Rhum Engl Ed; 1996 Feb; 63(2):141-4. PubMed ID: 8689286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytokines and diseases. Abnormal expression of interleukin 6 and diseases].
    Hirano T
    Nihon Naika Gakkai Zasshi; 1991 Sep; 80(9):1401-8. PubMed ID: 1761919
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in Lymphocyte cell surface markers in human disease states.
    Williams RC
    Clin Immunol Rev; 1981-1982; 1(3):409-69. PubMed ID: 6762279
    [No Abstract]   [Full Text] [Related]  

  • 5. The rational designed antagonist derived from the complex structure of interleukin-6 and its receptor affectively blocking interleukin-6 might be a promising treatment in multiple myeloma.
    Feng J; Yang Z; Li Y; Hu M; Yu M; Qin W; Sun J; Shen B
    Biochimie; 2006 Sep; 88(9):1265-73. PubMed ID: 16626851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How NKG2D ligands trigger autoimmunity?
    Caillat-Zucman S
    Hum Immunol; 2006 Mar; 67(3):204-7. PubMed ID: 16698443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IL-6 and autoimmune diseases].
    Yoshizaki K
    Nihon Rinsho Meneki Gakkai Kaishi; 1997 Dec; 20(6):507-9. PubMed ID: 9701844
    [No Abstract]   [Full Text] [Related]  

  • 8. The weight of interleukin-6 in B cell-related autoimmune disorders.
    Youinou P; Jamin C
    J Autoimmun; 2009; 32(3-4):206-10. PubMed ID: 19307104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.
    Hirota K; Hashimoto M; Yoshitomi H; Tanaka S; Nomura T; Yamaguchi T; Iwakura Y; Sakaguchi N; Sakaguchi S
    J Exp Med; 2007 Jan; 204(1):41-7. PubMed ID: 17227914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin 6 (IL-6)--clinical significance].
    Kamińska B; Gradowska L; Paczek L
    Pol Arch Med Wewn; 1996 Mar; 95(3):270-6. PubMed ID: 8755859
    [No Abstract]   [Full Text] [Related]  

  • 11. Autoimmune adrenalitis, asthma and membranoproliferative glomerulonephritis.
    Frey FJ; Trost B; Zimmermann A
    Am J Nephrol; 1991; 11(4):341-2. PubMed ID: 1799195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatitis C and immunologic anomalies].
    Lunel F
    Gastroenterol Clin Biol; 1994; 18(10):829-38. PubMed ID: 7875390
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin-18 and the treatment of rheumatoid arthritis.
    Dinarello CA
    Rheum Dis Clin North Am; 2004 May; 30(2):417-34, ix. PubMed ID: 15172050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular IL-1 alpha in fibroblasts as a possible endogenous mediator of joint damage in rheumatoid arthritis.
    Apte RN
    Isr J Med Sci; 1997 Apr; 33(4):285-8. PubMed ID: 9347881
    [No Abstract]   [Full Text] [Related]  

  • 15. [Abnormal gp130 signaling and autoimmune disease].
    Ishihara K; Atsumi T
    Tanpakushitsu Kakusan Koso; 2002 Dec; 47(16 Suppl):2336-42. PubMed ID: 12518458
    [No Abstract]   [Full Text] [Related]  

  • 16. Biological and clinical aspects of interleukin 6.
    Hirano T; Akira S; Taga T; Kishimoto T
    Immunol Today; 1990 Dec; 11(12):443-9. PubMed ID: 2127356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
    Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
    Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
    Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rheumatoid arthritis and multiple myeloma. Apropos of 22 cases. Results of a multicenter national survey].
    Flipo RM; Deprez X; Fardellone P; Duquesnoy B; Delcambre B
    Rev Rhum Ed Fr; 1993 Apr; 60(4):269-73. PubMed ID: 8167623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.